Developer docs
API playgroundTry for free, no card

Search company profiles

Nectome

Full company profile

uuid00043fv

Namestring
Nectome
Legal namestring
Nectome, Inc.
Websiteurl
nectome.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Nectome is a neuroscience company founded in 2015 by Aurelia Song (formerly Robert McIntyre) that has developed Aldehyde-Stabilized Cryopreservation (ASC), a whole-body, whole-brain preservation protocol. The technology combines chemical fixation using glutaraldehyde with cryoprotectants perfused through the body's own vascular system, preserving every synapse and nearly every protein, lipid, and nucleic acid at nanoscale, subsynaptic detail. The preserved body is stable for hundreds of years at -32°C — a much higher and more resilient storage temperature than traditional cryonics at -196°C — and is also compatible with traditional funeral practices at room temperature for months. The protocol was refined over a decade of R&D and has been independently verified by the Brain Preservation Foundation (both Small and Large Mammal Brain Preservation Prizes) and by Andrew Critch of the Survival and Flourishing Fund via electron microscopy at UC Berkeley.

The company sells preservation services directly to terminally ill individuals who plan to use medical aid-in-dying (MAiD), with the preservation procedure required to begin within 12 minutes of death. As of May 2026, Nectome offers full-price sales at $250,000 per preservation through a simple "buy a preservation, get a preservation" model — no memberships, insurance, or complex contracts. Customers sign one document, pay, and receive one transferable preservation that can be used for themselves or a loved one. All procedures are performed at a planned preservation center in the Oregon foothills, chosen specifically for the state's MAiD legal framework and supportive community. Nectome operates with an 11-50 person team, has raised approximately $670K cumulatively (notably $120K from Y Combinator in 2018 and a $550K grant from the Survival and Flourishing Fund in 2025), and reaches its audience primarily through a Substack publication, a Discord community, and direct email outreach.

Short descriptiontext

Nectome is a neuroscience company that sells whole-body, whole-brain human preservation services using its proprietary Aldehyde-Stabilized Cryopreservation protocol, targeting terminally ill individuals planning medical aid-in-dying procedures at $250,000 per preservation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human preservation services, brain cryopreservation, end-of-life planning, aldehyde-stabilized cryopreservation, connectomics preservation
NAICS code2 codes
  • Funeral Homes and Funeral Services81221
  • Death Care Services8122
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Surgical & Medical Instruments & Apparatus3841
Product category
End-of-Life Human Preservation Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preservation Services Sale
TypeOne Time License
Description

One-time purchase of preservation services ('buy a preservation, get a preservation' model). No memberships, insurance, or complex arrangements. Customer signs one document, pays, and is entitled to one preservation that can be used for themselves or a loved one. Transferable - if the designated person is not eligible, it can be used for someone else or resold.

articles.nectome.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
Pricing details1 tier
1Full-price preservation at $250,000
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Currently offering full-price sales at $250k as of 5/11/2026. Watch this space for future deals for select communities.

articles.nectome.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Nectome provides whole-body, whole-brain human end-of-life preservation services using Aldehyde-Stabilized Cryopreservation (ASC). The protocol uses chemical fixation with glutaraldehyde and cryoprotectants perfused through the body's vascular system to preserve every synapse, cell, protein, lipid, and nucleic acid at nanoscale detail for potential future revival. Preservation must be planned in advance and performed within 12 minutes post-mortem in conjunction with medical aid-in-dying, with procedures executed at a planned Oregon preservation center.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Every synapse and almost every protein, lipid, and nucleic acid preserved throughout the entire body
+3 more records
Product overview1 text field

Nectome offers a single core service: whole-body, whole-brain human end-of-life preservation using Aldehyde-Stabilized Cryopreservation (ASC). The company was founded by Aurelia Song and has developed a protocol that preserves every synapse and cell at nanoscale detail, compatible with traditional funeral practices. As of 2026, Nectome is conducting pre-sales of its preservation service at $250,000, with operations based in the Oregon foothills. The company supports its service with an educational Substack blog series called 'The Preservation Sequences' that explains the scientific basis and methodology.

Product and service1 record
1Whole-Body, Whole-Brain Preservation Service
CategoryEnd-of-life preservation services
Description

End-of-life preservation service for terminally ill individuals, performed within 12 minutes post-mortem via aldehyde-stabilized cryopreservation to preserve every synapse and cell at nanoscale detail for potential future revival. Sold as a transferable one-time preservation right for $250,000, with the preserved body stored at -32°C and compatible with traditional funeral practices at room temperature.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Brain Preservation Foundation (BPF)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ken Hayworth, president of BPF and neuroscientist at Janelia/HHMI, conducted independent verification of Nectome's preservation methods. He witnessed 3-day marathon preservation of rabbit and pig brains, secured samples with tamper-proof stickers, and performed cutting and imaging at Janelia. Sebastian Seung (Princeton/MIT) joined the judging panel. BPF uses FIB-SEM imaging at up to 4nm resolution to evaluate synaptic traceability. BPF released all images and 3D data files publicly. Nectome won both Small and Large Mammal Brain Preservation Prizes.

articles.nectome.com
Strategic tierSupportingTypeTechnology or Integration
Description

Andrew Critch brought preserved rat brain samples to Berkeley EM Core for electron microscopy imaging. Dr. Danielle Jorgens and Reena Zalpuri provided advice and assistance in experiment planning, electron microscopy sample preparation, and data collection. The lab performed FIB-SEM imaging of samples stored at both -32°C and 60°C to compare preservation quality.

3Professor Bobby Kasthuri (U Chicago)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Neuroscientist consulted during Andrew Critch's independent evaluation of Nectome's preservation technology. Kasthuri reviewed electron microscopy sample quality as part of the third-party validation process.

articles.nectome.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Alcor is the largest US cryonics organization offering whole-body and neuropreservation at liquid nitrogen temperatures (-196°C). Directly comparable to Nectome as both sell end-of-life human preservation services with long-term storage, though Alcor uses traditional cryopreservation rather than ASC.

TypeDirect peer
Description

Michigan-based non-profit offering whole-body and neuro cryopreservation services since 1976. Directly competes with Nectome in the same end-of-life preservation market with a lower price point and longer operational track record.

TypeEmerging player
Description

Berlin-based startup offering human cryopreservation with a tech-forward brand and standby team model. Comparable as a venture-backed emerging player attempting to modernize and grow the preservation market, though geographically focused on Europe.

4Oregon Cryonics
TypeRegional player
Description

Small Pacific Northwest cryonics organization based in the same region as Nectome. Provides traditional cryopreservation services with local standby capability; competing regionally for the same MAiD-eligible client base.

TypeDirect peer
Description

Florida-based provider of cryopreservation standby, stabilization, and transport services for cryonics organizations including Alcor and CI. Comparable as a service provider in the same preservation value chain, focused on the procedural side rather than long-term storage.

TypeBroad incumbent
Description

Commercial longevity biotech selling NAD+ boosting consumer health products. Operates broadly in the human longevity/lifespan extension space and addresses overlapping customer interest in life extension, though with a different product category (consumer supplements vs. preservation services).

7Yinfeng Cryonics
TypeRegional player
Description

Chinese cryonics organization founded with Shandong University Yinfeng Biological Group. Comparable as a regional cryonics provider serving an emerging market, though focused on Asia and not directly competing with Nectome in the US.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nectome

End-of-Life Human Preservation Servicesnectome.com

Nectome is a neuroscience company that sells whole-body, whole-brain human preservation services using its proprietary Aldehyde-Stabilized Cryopreservation protocol, targeting terminally ill individuals planning medical aid-in-dying procedures at $250,000 per preservation.

What Nectome does

Nectome is a neuroscience company founded in 2015 by Aurelia Song (formerly Robert McIntyre) that has developed Aldehyde-Stabilized Cryopreservation (ASC), a whole-body, whole-brain preservation protocol. The technology combines chemical fixation using glutaraldehyde with cryoprotectants perfused through the body's own vascular system, preserving every synapse and nearly every protein, lipid, and nucleic acid at nanoscale, subsynaptic detail. The preserved body is stable for hundreds of years at -32°C — a much higher and more resilient storage temperature than traditional cryonics at -196°C — and is also compatible with traditional funeral practices at room temperature for months. The protocol was refined over a decade of R&D and has been independently verified by the Brain Preservation Foundation (both Small and Large Mammal Brain Preservation Prizes) and by Andrew Critch of the Survival and Flourishing Fund via electron microscopy at UC Berkeley.

The company sells preservation services directly to terminally ill individuals who plan to use medical aid-in-dying (MAiD), with the preservation procedure required to begin within 12 minutes of death. As of May 2026, Nectome offers full-price sales at $250,000 per preservation through a simple "buy a preservation, get a preservation" model — no memberships, insurance, or complex contracts. Customers sign one document, pay, and receive one transferable preservation that can be used for themselves or a loved one. All procedures are performed at a planned preservation center in the Oregon foothills, chosen specifically for the state's MAiD legal framework and supportive community. Nectome operates with an 11-50 person team, has raised approximately $670K cumulatively (notably $120K from Y Combinator in 2018 and a $550K grant from the Survival and Flourishing Fund in 2025), and reaches its audience primarily through a Substack publication, a Discord community, and direct email outreach.

Nectome firmographics

Firmographics
Name
Nectome
Legal name
Nectome, Inc.
Website
https://nectome.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Nectome is a neuroscience company that sells whole-body, whole-brain human preservation services using its proprietary Aldehyde-Stabilized Cryopreservation protocol, targeting terminally ill individuals planning medical aid-in-dying procedures at $250,000 per preservation.
Ownership category
akta.pro rank

Where Nectome is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Nectome business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Preservation Services Sale: One-time purchase of preservation services ('buy a preservation, get a preservation' model). No memberships, insurance, or complex arrangements. Customer signs one document, pays, and is entitled to one preservation that can be used for themselves or a loved one. Transferable - if the designated person is not eligible, it can be used for someone else or resold.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goFull-price preservation at $250,000

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Nectome product offering

Product offering

Core offering

Nectome provides whole-body, whole-brain human end-of-life preservation services using Aldehyde-Stabilized Cryopreservation (ASC). The protocol uses chemical fixation with glutaraldehyde and cryoprotectants perfused through the body's vascular system to preserve every synapse, cell, protein, lipid, and nucleic acid at nanoscale detail for potential future revival. Preservation must be planned in advance and performed within 12 minutes post-mortem in conjunction with medical aid-in-dying, with procedures executed at a planned Oregon preservation center.

Product overview

Nectome offers a single core service: whole-body, whole-brain human end-of-life preservation using Aldehyde-Stabilized Cryopreservation (ASC). The company was founded by Aurelia Song and has developed a protocol that preserves every synapse and cell at nanoscale detail, compatible with traditional funeral practices. As of 2026, Nectome is conducting pre-sales of its preservation service at $250,000, with operations based in the Oregon foothills. The company supports its service with an educational Substack blog series called 'The Preservation Sequences' that explains the scientific basis and methodology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Whole-Body, Whole-Brain Preservation Service End-of-life preservation service for terminally ill individuals, performed within 12 minutes post-mortem via aldehyde-stabilized cryopreservation to preserve every synapse and cell at nanoscale detail for potential future revival. Sold as a transferable one-time preservation right for $250,000, with the preserved body stored at -32°C and compatible with traditional funeral practices at room temperature.

Quantifiable outcome

  • Every synapse and almost every protein, lipid, and nucleic acid preserved throughout the entire body
  • +3 more outcomes

Companies that use Nectome

Customer profile

Segments1 record

Ideal customer profiles1 record

Nectome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Nectome partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • Brain Preservation Foundation (BPF)coreStrategic or Co-development PartnerKen Hayworth, president of BPF and neuroscientist at Janelia/HHMI, conducted independent verification of Nectome's preservation methods. He witnessed 3-day marathon preservation of rabbit and pig brains, secured samples with tamper-proof stickers, and performed cutting and imaging at Janelia. Sebastian Seung (Princeton/MIT) joined the judging panel. BPF uses FIB-SEM imaging at up to 4nm resolution to evaluate synaptic traceability. BPF released all images and 3D data files publicly. Nectome won both Small and Large Mammal Brain Preservation Prizes.
  • University of California Berkeley Electron Microscope LaboratorysupportingTechnology or IntegrationAndrew Critch brought preserved rat brain samples to Berkeley EM Core for electron microscopy imaging. Dr. Danielle Jorgens and Reena Zalpuri provided advice and assistance in experiment planning, electron microscopy sample preparation, and data collection. The lab performed FIB-SEM imaging of samples stored at both -32°C and 60°C to compare preservation quality.
  • Professor Bobby Kasthuri (U Chicago)supportingStrategic or Co-development PartnerNeuroscientist consulted during Andrew Critch's independent evaluation of Nectome's preservation technology. Kasthuri reviewed electron microscopy sample quality as part of the third-party validation process.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Nectome competitors and assessment

Company assessment

Direct peers

  • Alcor Life Extension Foundation: Alcor is the largest US cryonics organization offering whole-body and neuropreservation at liquid nitrogen temperatures (-196°C). Directly comparable to Nectome as both sell end-of-life human preservation services with long-term storage, though Alcor uses traditional cryopreservation rather than ASC.
  • Cryonics Institute: Michigan-based non-profit offering whole-body and neuro cryopreservation services since 1976. Directly competes with Nectome in the same end-of-life preservation market with a lower price point and longer operational track record.
  • Suspended Animation: Florida-based provider of cryopreservation standby, stabilization, and transport services for cryonics organizations including Alcor and CI. Comparable as a service provider in the same preservation value chain, focused on the procedural side rather than long-term storage.

Emerging players

  • Tomorrow Biostasis: Berlin-based startup offering human cryopreservation with a tech-forward brand and standby team model. Comparable as a venture-backed emerging player attempting to modernize and grow the preservation market, though geographically focused on Europe.

Regional players

  • Oregon Cryonics: Small Pacific Northwest cryonics organization based in the same region as Nectome. Provides traditional cryopreservation services with local standby capability; competing regionally for the same MAiD-eligible client base.
  • Yinfeng Cryonics: Chinese cryonics organization founded with Shandong University Yinfeng Biological Group. Comparable as a regional cryonics provider serving an emerging market, though focused on Asia and not directly competing with Nectome in the US.

Broad incumbents

  • Elysium Health: Commercial longevity biotech selling NAD+ boosting consumer health products. Operates broadly in the human longevity/lifespan extension space and addresses overlapping customer interest in life extension, though with a different product category (consumer supplements vs. preservation services).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Nectome social profiles

Digital presence

Nectome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nectome leadership team

Management profile

Number of profiles

Profiles1 record

Nectome funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nectome M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nectome

What does Nectome do?

Nectome provides whole-body, whole-brain human end-of-life preservation services using Aldehyde-Stabilized Cryopreservation (ASC). The protocol uses chemical fixation with glutaraldehyde and cryoprotectants perfused through the body's vascular system to preserve every synapse, cell, protein, lipid, and nucleic acid at nanoscale detail for potential future revival. Preservation must be planned in advance and performed within 12 minutes post-mortem in conjunction with medical aid-in-dying, with procedures executed at a planned Oregon preservation center.

Is Nectome a public or private company?

Nectome is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nectome founded?

Nectome was founded in 2015. It employs 1 to 10 people.

Where is Nectome based?

Nectome is headquartered in Mountain View, United States, in the North America region.

How does Nectome make money?

One revenue line is on record: preservation Services Sale.

Who are Nectome's main competitors?

Direct peers on record are Alcor Life Extension Foundation, Cryonics Institute and Suspended Animation. Tomorrow Biostasis is listed as an emerging player. Regional players are Oregon Cryonics and Yinfeng Cryonics. Elysium Health is listed as a broad incumbent.

Does Nectome have an API?

No public API is recorded for Nectome.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireAfterlife: freeze and uploadNectome, a cryopreservation startup, has a waiting list including Sam Altman, who paid a $10,000 deposit. A survey of over 300 US physicians found the median probability of future revival at 25.5%. The article discusses technical challenges and ethical concerns, noting whole-brain emulation remains far off.New ScientistMajor leap towards reanimation after death as mammal’s brain preservedNectome, a research company in Portland, Oregon, has successfully preserved a pig's brain using a protocol compatible with physician-assisted death to lock in cellular activity and neural structures. The company intends to offer this service to terminally ill patients to preserve their brains indefinitely for potential future reconstruction of their minds. While the technique shows excellent preservation of minute structures, experts note that current technology cannot revive such organs or reconstruct consciousness.LifespanThe Tale of One Tower: SF-Based Vertical Longevity VillageThree German entrepreneurs—Jakob Drzazga, Christian Nagel, and Christian Peters—purchased a 16-story tower in San Francisco's Mid-Market area for $11 million in March to create a co-working and co-ideation hub for longevity, AI, crypto, and robotics, hosting a six-week pop-up village called Viva Frontier Tower. The tower, operated by startup BerlinHouse, features purpose-built floors including a longevity floor run by Laurence Ion (co-creator of VitaDAO) and includes robotics and biochemistry labs, with memberships starting at $190 monthly. The inaugural longevity conference brought together researchers and entrepreneurs from companies including Kernel, Nectome, and Eon Systems to discuss topics ranging from cellular senescence to mind uploading, as part of a broader vision to eventually establish permanent longevity communities.Connecting the Human Brain with DDIConnectomics Part II: Your Future Self Will Thank YouThis article serves as a summary and show notes for Part II of a series on connectomics, featuring discussions with experts from the Brain Preservation Foundation, Nectome, and Google. The content highlights technical research tools such as fixation protocols, multimodal imaging, and machine intelligence used to interpret neural data. It references specific scientific papers and collaborations, including work between Google and HHMI on releasing the Drosophila Hemibrain Connectome.Slate MagazineWhat Would It Mean for Humans to Become Data?An analysis of the HBO/BBC miniseries 'Years and Years' explores its depiction of transhumanism, where characters seek to digitize human consciousness to achieve immortality. The article highlights specific companies such as Brain Backups, Nectome, and LifeNaut that are actively working on technologies to map, preserve, or backup the human brain and consciousness.ForbesData Governance, AI And Healthcare: An Exciting New World Of Health ProvisionAI data governance in healthcare is discussed, citing GDPR infractions and Nectome's brain-uploading trial. The UK government is investing in data governance, and the article argues that proper regulation is needed before AI can enable advanced medical applications like brain uploading.Atlanta Journal-ConstitutionMIT cuts ties with startup aiming to save brain with fatal procedureMIT cut ties with Nectome, a startup that proposed preserving human brains after death using high-tech embalming. The procedure is 100 percent fatal, but the company claimed it could keep a body intact for hundreds of years. The partnership was announced last month.GizmodoMIT Backs Away From Startup That Aims to Preserve Your Brain and Memories After You DieMIT terminated its subcontract with Nectome, a startup developing brain-preservation technology for potential mind uploading. The decision followed concerns that neuroscience has not advanced enough to preserve memories or recreate consciousness. Nectome clarified it does not offer clinical brain preservation and plans to continue research.BBCBrain back-up firm Nectome loses link to MITMIT announced it is severing ties with Nectome, a brain-backup firm that proposed preserving biomolecules to store memories after death. The university cited insufficient neuroscience advancement, while Nectome acknowledged the decision and noted its work is at an early stage.TechCrunchMIT cuts ties with brain preservation startup NectomeMIT terminated its subcontract with Nectome, a brain preservation startup, after reviewing its scientific premises. The company had collected $10,000 refundable payments for a wait list, but MIT said neuroscience has not advanced enough to validate the procedure. MIT did not rule out future brain preservation but said the science is not solid.